GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

NUVB · Jun 30, 2026

Nuvation Bio Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001193125-26-336646General Corporate
Debt relative to revenueRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.debt_to_revenue

765.69% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generation88thOwn-history percentile · N=8
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-135.60% · OPTIONAL · VALID

Revenue growthRAWCurrent state valid · history insufficient
Evidence method

Yoy · gp.fundamentals.revenue

555.64% · CORE · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

62.80% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating margin88thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.operating_margin

-161.06% · CORE · VALID

R&D intensity13thOwn-history percentile · N=8
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

96.76% · OPTIONAL · VALID

SBC intensity13thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

33.01% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History9 statesHistory building
Jun 30, 20240/5 normalizedLevel 3Sep 30, 20240/5 normalizedLevel 3Dec 31, 20240/5 normalizedLevel 3Mar 31, 20250/6 normalizedLevel 3Jun 30, 20250/8 normalizedLevel 3Sep 30, 20250/8 normalizedLevel 3Dec 31, 20250/7 normalizedLevel 3Mar 31, 20260/7 normalizedLevel 3Jun 30, 20264/7 normalizedLevel 3
Period transition

What moved in the state?

Balance Sheet Leverage Increased
Previous
56.86%
Current
765.69%
Delta
708.83%
Cash Generation Decreased
Previous
6.09%
Current
-135.60%
Delta
-141.69%
Growth Decreased
Previous
2598.70%
Current
555.64%
Delta
-2043.06%
Inventory Pressure Increased
Previous
19.04%
Current
62.80%
Delta
43.77%
Profitability Decreased
Previous
4.66%
Current
-161.06%
Delta
-165.73%
R And D Intensity Increased
Previous
42.11%
Current
96.76%
Delta
54.65%
Sbc Intensity Increased
Previous
10.85%
Current
33.01%
Delta
22.16%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Compared To · Pharmaceutical Preparations peers →Derived From · NUVB Company Quality Vector →Has State · Nuvation Bio Inc. →Transitioned To · NUVB R_AND_D_INTENSITY_INCREASED →Transitioned To · NUVB SBC_INTENSITY_INCREASED →Transitioned To · NUVB Fundamental State →Transitioned To · NUVB BALANCE_SHEET_LEVERAGE_INCREASED →Transitioned To · NUVB CASH_GENERATION_DECREASED →Transitioned To · NUVB GROWTH_DECREASED →Transitioned To · NUVB INVENTORY_PRESSURE_INCREASED →Transitioned To · NUVB PROFITABILITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.